logical properties of the newly introduced sulfonamide drugs after animal studies have been carried out, observations are recorded in this paper on the absorption, excretion, diffusion into body fluids, and acetylation of sulfadiazine in man. These studies were made in part on individuals not receiving chemotherapeutic treatment, in part on patients with acute infections, mostly pneumococcal pneumonia undergoing therapy with sulfadiazine.
Previous studies on the absorption and excretion of sulfadiazine in man, made by Plummer and Ensworth,"2 indicate that this drug is rapidly absorbed into the blood stream following oral ingestion of the drug. They obtained comparatively high blood concentrations, with the level falling more slowly than with sulfathiazole but somewhat more rapidly than with sulfapyridine. Conjugation of sulfadiazine was low. In two cases, wherein urinary excretion was followed for a sufficiently long period, approximately 80 per cent of the ingested drug was excreted by the kidneys.
Very recently, Reinhold and his associates"4 have confirmed the above findings for man and present further data on the urinary excretion and diffusion into the various body fluids. They found that 47 to 85 per cent of sulfadiazine was excreted by the kidney within 48 hours following a single oral dose of 3 grams. Sulfadiazine was found to penetrate readily into the pleural and peritoneal cavities, and 24 hours after the administration of an initial dose the cerebrospinal fluid contained appreciable quantities of the drug.
Materials and methods
Observations on the rate of absorption of sulfadiazine from the gastrointestinal tract, as measured by frequent determinations of blood concentration following a single oral dose of 0.06 gm./K per os, were made twice in each of two normal males and compared with the data obtained following two similar intravenous doses of sodium sulfadiazine in another individual. In addition, in order to provide information on the range of individual variation, the blood concentration attained 4 hours after a single initial oral dose of 4.0 gm. of sulfadiazine was determined in 24 patients.
Nine studies on the excretion of sulfadiazine in the urine, either following a single dose of 0.06 gm./K or an initial dose of 4.0 gm. per os followed by 1.0 gm. every 6 hours, were conducted in 7 individuals over varying periods of time.
The rate and amount of diffusion of sulfadiazine into body fluids, as measured by simultaneously determined blood concentrations, were studied in 22 instances, either after a single dose of 4.0 gm. of sulfadiazine given orally or an initial dose of 4.0 gm. followed by 1 In all the foregoing observations the concentration of both free and total sulfadiazine was determined, thus providing a mass of material on the degree of acetylation which occurs in man.
The method of Bratton and Marshall,3 using N-(1-napkthyl)ethylenediamine hydrochloride as the coupling component, was used in determining the concentration of sulfadiazine in blood, urine, and body fluids. Readings were made with the Evelyn photoelectric colorimeter, using the 10 cc. aperture and No. 540 filter. A 1: 80 dilution of blood and body fluids and appropriate dilutions of urine were employed. The only other deviations* from the method of Bratton and Marshall were (1) the substitution of an 0.033 N solution of sodium nitrite in place of 0.1 N sodium nitrite, and (2) the use of 0.5 cc. of 8 N HCI with heating for 30 minutes in the boiling water-bath for determination of the conjugated fraction. These modifications gave results with a maximum minus error of less than 10 per cent. Table 1. slowly, with a not inconsiderable concentration being present 24 hours after administration, and from 0.4 to 0.7 mgm. per cent sulfadiazine still being found in the blood 48 hours after administration. This indicates ready absorption, fairly comparable to but somewhat slower than that of sulfanilamide and sulfathiazole, but with an apparent slow rate of excretion, reminiscent of sulfapyridine. Since the curve represents a composite of absorption, diffusion, and excretion, it should be nloted that only 7.6 to 13.6 per cent of the ingested drug was excreted during the first 6-hour period. This is in decided contrast to the excretion of sulfathiazole"6 noted in our previous studies, and will be commented on later. Absorption of sulfadiazine from the gastro-intestinal tract may be expected to vary considerably from individual to individual, as shown with sulfapyridine2 and sulfathiazole." The results of observations on blood concentration 4 hours after an initial dose of 4.0 gm. of sulfadiazine in 24 cases, of whom 8 had pneumococcal pneumonia and the remainder had miscellaneous conditions not under treatment, are shown in Table 2 . The concentrations found ranged from 0.9 to 8.0 mgm. per cent, the majority falling between 2.0 and 4.9 mgm. per cent. These figures obviously indicate a considerable individual variation in the rate of absorption of sulfadiazine and are comparable to similar variations found with sulfapyridine and sulfathiazole. That absorption may be especially poor in the presence of disease is indicated by the fact that the 3 lowest concentrations found, all below 2.0 mgm. per cent, were obtained from patients with lobar pneumonia who were severely ill.
For comparison, the curve of blood concentration following a single intravenous dose of 3.0 gm. (0.06 gm./K body weight) of sodium-sulfadiazine is illustrated in Fig. 3 of sulfadiazine following intravenous injection of the sodium salt is more quantitative and more regular than that seen with oral ingestion of sulfadiazine itself. In 6 hours, approximately 42 per cent of the sulfadiazine administered intravenously was excreted in the urine as contrasted with an excretion of 8 to 14 per cent during a similar period when the acid salt had been taken per os. Similarly, during a 24-hour period, 73 to 76 per cent of the intravenously administered drug was excreted, in comparison to a 30 to 55 per cent excretion of the ingested drug. In addition, the peak of excretion of the orally administered sulfadiazine was ordinarily found in the second 6-hour period, while the peak found with the intravenous salt was during the first 6-hour period. These facts, when compared with previous data on sulfathiazole,16 would indicate that sulfadiazine is absorbed and excreted somewhat more slowly than is sulfathiazole. These facts are probably an important factor in the explanation for the maintenance of a sustained blood concentration of sulfadiazine over longer periods of time than is the case with sulfathiazole.
In order to obtain information concerning variations in the amount of sulfadiazine excreted in the urine in cases under continued treatment, similar observations were made in 5 patients who received the drug over periods of time ranging from 1 to 4 days. I'he summarized data are shown in Table 4 , from which it will be seen that the amount of administered drug recovered in the urine was surprisingly constant.
Diffusion into body fluids
Data concerning the rate and degree of diffusion into pleural and ascitic fluids are shown in Table 5 . In three observations 4 hours after an oral dose of 4.0 gm. of sulfadiazine the concentration of total sulfadiazine in the fluids varied between 24 and 68 per cent . , f x .
These observations indicate that sulfadiazine diffuses readily and at a fairly rapid rate into pleural and ascitic fluids, the results being essentially similar to those obtained with sulfapyridine and sulfa- These observations indicate that sulfadiazine diffuses fairly well into the non-inflammatory cerebrospinal fluid within 12 to 18 hours, though at a slower rate and at a somewhat lower concentration than sulfanilamide and sulfapyridine. A comparison of sulfadiazine, sulfathiazole, and sulfapyridine is shown in Fig. 4 .
Experiments carried out with the intravenous injection of a similar quantity of the sodium salt of sulfadiazine, as shown in Table 6 , indicate that the relative concentration of spinal fluid sulfadiazine as compared with blood sulfadiazine after 4 hours is only slightly greater than in the experiments following the administration of sulfadiazine per os. However, it should be noted that the actual concentration of the drug itself in the spinal fluid is much higher with the intravenous injection of the sodium salt. This fact at once suggests the desirability of using the sodium salts of the sulfonamide compounds intravenously in the initial treatment of acute meningitis.
Variations In this series are included 12 patients with pneumococcal lobar pneumonia, two patients with miscellaneous infections, and 24 patients undergoing chemotherapeutic study. The dosage employed in those patients under continuous treatment consisted of an initial dose of 4.0 gm., followed by 1.0 gm. q. 6 h. No cases with renal disease or marked congestive heart failure are induded. The 4-hour blood concentration determinations were made on samples of blood collected 4 hours after the initial dose of 4.0 gm. and 2 hours prior to the first 1.0 gm. dose of the maintenance treatment. All other determinations were made on samples of blood collected at approximately 8:00 A.M., 6 hours after the regular 2:00 A. M. dose of 1.0 gm. and just before the 8:00 A. M. dose. The day on which therapy was begun was considered the first day of treatment, irrespective of the time that sulfadiazine was started, the second day of treatment beginning at 7:00 A. M. on the following day, and so on.
The data recorded in Fig. 5 show a wide variation in blood levels both during the early hours of treatment and by the third day and later, though in general from the third day on a probable satisfactory therapeutic level is obtained in nearly all cases. The median level would appear to be higher than that obtained with sulfathiazole16 from the third day of therapy and on. In a number of patients in this series, determinations of the concentration of sulfadiazine in the blood were made at various intervals after the last dose of the drug had been given. These observations are recorded in Table 7 and demonstrate that not inconsiderable concentrations of sulfadiazine may be present 18 and 24 hours after discontinuance of the drug. Indeed, concentrations of 0.5 to 2.1 nigm. per cent of total sulfadiazine were found even 48 hours later.
Since none of these cases exhibited evidences of renal functional impairment or congestive cardiac failure, conditions which may seriously affect the renal excretion of sulfathiazole,16 these observations further support the views that sulfadiazine is less rapidly excreted than is sulfathiazole.
Acetylation of sulfadiazine The importance of acetylation of the sulfonamide compounds is well known. Not only is the conjugated form therapeutically inactive but also by virtue of its high insolubility in urine it fosters the production of hematuria and anuria, as has been repeatedly reported in sulfapyridine"7 19 and sulfathiazole5 6' 7' 11 therapy.
The degree of acetylation of sulfadiazine has been studied from day to day in a series of patients. As representative of the group the data on the same patients included in 35 Fig. 5 16 Reference to Tables 1, 3 , and 4 will show that the percentage of acetylated sulfadiazine found in the urine tends to be somewhat higher than is the case with sulfathiazole.1' This may possibly be related to the greater solubility of the acetyl derivative of sulfadiazine in urine, as demonstrated by Feinstone and his associates. 4 Analysis of the data in Table 5 indicates that acetylated sulfadiazine does not diffuse so rapidly into pleural and ascitic fluids as does free sulfadiazine, only free drug being present in the 4-hour specimens when the acetyl compound was already present in the blood. It has already been pointed out that only free sulfadiazine was found in spinal fluids, even as long as 24 to 96 hours after the initial dose of the drug was administered.
Discussion
The foregoing observations on the pharmacological properties of sulfadiazine indicate that absorption of the drug is sufficiently rapid to yield satisfactory blood concentrations within 4 to 6 hours after an initial dose of 4.0 gm. in the average case and that an appropriate blood level may be obtained by 12 In agreement with others it has been demonstrated that sulfadiazine is conjugated to only a small degree; hence, the necessity for determining the conjugated drug may be eliminated for routine purposes.
Though the urinary concentration of the acetylated derivative tends to be somewhat higher with sulfadiazine than with sulfathiazole, the greater solubility of the former in urine would possibly lead one to believe that the drug may not produce calculi in the urinary tract of man. Experimental evidence in support of this possibility has already been provided by Feinstone and his collaborators,4 who found no postmortem urinary calculi or histological changes in the kidneys of monkeys treated with sulfadiazine, except in those animals which were on an extraordinarily high dosage of the drug. In addition, we have found it unusually difficult to find crystals of acetylated sulfadiazine in the urine of patients under study, even after chilling the urine for several hours in the ice-box. In only one case have sheaf-like crystals been found in the urine and then only after chilling and in such small numbers that it was impossible to collect a sample for chemical analysis. The crystals were essentially similar in appearance to those of acetylated sulfathiazole, 1 resembling bound sheaves of wheat.
The ready diffusion of sulfadiazine into pleural and ascitic fluids suggests the probable efficacy of this compound in the early stages of suitable infection of these body cavities. The rather slow rate of diffusion into the spinal fluid on the other hand suggests the desirability of the initial use of the sodium salt of sulfadiazine intravenously in the treatment of meningeal infections.
We have not had sufficient experience with sulfadiazine to offer any statistics on its toxic manifestations. Suffice it to say, however, that in 16 patients receiving the drug for periods of from 3 to 8 days, and in 24 patients receiving the drug for a period of less than 3 days, only two toxic reactions have been seen. In one instance, a patient experienced vertigo during the first 16 hours, which disappeared despite maintenance of therapy. The second patient, a 69-year-old woman with a pneumococcus Type III otitis media, developed drug fever without skin eruption on the 6th day of therapy. The maxinium temperature was 1020 F. and the temperature was normal within 72 hours after discontinuance of the drug. In not a single instance was nausea or vomiting observed, and no effects on the hemapoietic or urinary systems were encountered. Summary Observations on the absorption, excretion, diffusion, and acetylation of sulfadiazine in man have been presented. They show (1) that sulfadiazine is readily absorbed in most instances but is not rapidly excreted; (2) that there is considerable individual variation in capacity to absorb the drug, though not enough to interfere with the use of a standard dosage in the majority of patients; (3) that sulfadiazine readily diffuses into pleural and ascitic fluids and at a somewhat slower rate into the cerebrospinal fluid; (4) that acetylation of sulfadiazine in the blood is only slight, rarely exceeding 20 per cent, but is somewhat higher in the urine though rarely sufficient to cause precipitation of crystals, presumably because of its relatively high solubility; and (5) that limited experience with the drug suggests a low degree of toxicity. Finally, some of the clinical implications of these observations on the pharmacological properties of sulfadiazine have been briefly discussed.
